Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6590511 | 0.94 | F10 (1.00) | F10 | |
| SCHEMBL6592241 | 0.92 | F10 (1.00) | F10 | |
| SCHEMBL6593450 | 0.92 | F10 (1.00) | F10 | |
| SCHEMBL6590441 | 0.91 | F10 (1.00) | F10 | |
| SCHEMBL6590329 | 0.91 | F10 (1.00) | F10 | |
| SCHEMBL6593805 | 0.90 | F10 (1.00) | F10 | |
| SCHEMBL6594123 | 0.90 | F10 (0.89) | F10 | |
| SCHEMBL6592001 | 0.90 | F10 (0.81) | F10 | |
| SCHEMBL6590281 | 0.89 | F10 (1.00) | F10 | |
| SCHEMBL6591158 | 0.89 | F10 (1.00) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040108-B1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AG (DE) | 2004-02-25 | — | — | EP | claimed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | claimed |
| US-20070111947-A1 | Fibrin targeted therapeutics | MCMURRY THOMAS J | 2007-05-17 | — | — | US | disclosed |
| WO-2007047608-A2 | FIBRIN TARGETED THERAPEUTICS | EPIX PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| EP-1040108-B1 | ORTHO-ANTHRANILAMIDE DERIVATIVES AS ANTI-COAGULANTS | SCHERING AG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-6498185-B1 | ENZYME FACTOR XA INHIBITORS | BERLEX LABORATORIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-6380221-B1 | FOR THERAPY OF DISEASE-STATES CHARACTERIZED BY THROMBOTIC ACTIVITY | BERLEX LABORATORIES, INC. | 2002-04-30 | — | — | US | disclosed |
| US-6140351-A | FOR TREATING THROMBOSIS | BERLEX LABORATORIES, INC. (US) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111947-A1 | Fibrin targeted therapeutics | FGB, F13B, F2 | F10 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.